glp-1/glucagon dual receptor agonist GLP-1 Agonists Explained for Pharmacy & Medical Students: Mechanism, Uses, and Side Effects Dual GLP-1/GIP Agonist | Tirzepatide

Populations most likely to benefit include individuals with obesity or central adiposity, insulin resistance or type 2 diabetes, metabolic dysfunctionassociated fatty liver disease, or elevated cardiovascular risk

According to Lilly, Medi-Cal (Californias Medicaid program) covers Zepbound with no prior authorization required

Liraglutide Liraglutide, trade name Victoza, was developed by Novo Nordisk

Compounded semaglutide injections start at $149 per month, and compounded tirzepatide injections start at $249 per monthboth at flat rates regardless of dose level

Discussion GLP-1RA fills increased rapidly between 2018 and 2023

Am J Cardiovasc Drugs 22(1):6981